Venn Therapeutics, a privately held immuno-oncology company focused on developing novel, early-stage cancer therapies, announced today that Mr. Paul Krysiak has been appointed to its board of directors.
Paul is a strong business leader with 17 years of biopharmaceutical industry experience focused on rare diseases and oncology. Currently, he serves as the President & CEO of Seva Therapeutics, an innovative oncology company. His previous experience includes CEO of 3G Therapeutics, VP of Sales and Business Development at EmpiraMed, VP of Commercial and Operations at Ceerdis Corporation, Area Director & GM at BioMarin Pharmaceuticals, as well as progressive sales and marketing management roles at Genzyme Corporation. Paul started his career in general and specialty sales at Merck.
Paul obtained BSc. in both Biomedical Sciences and Biochemistry from the University of Guelph, MSc. in Molecular Physiology from the University of Western Ontario and executive business training from the Ivey Business School.
Paul is passionate about adding value to patient and medical communities.
“We welcome Paul at a critical juncture of our journey as we pivot from a pre-clinical company to a clinic ready company. His experience and entrepreneurial background will serve Venn well as it nears critical milestones for shareholders, investors and most importantly the patients with unmet medical needs” said Venn CEO, Sam Shrivastava.
Mr. Krysiak added, “I think Venn is at a perfect inflection point for me to come on-board and help unlock its value proposition. Venn is developing very unique and highly promising oncology assets. I have been impressed by what Sam and team have been able to put together in a relatively short time with limited resources. His resourcefulness and innate gift to spot emerging trends in oncology has attracted my attention. I am looking forward to formally help Venn become a powerhouse in bringing innovation to the industry and the patient community at a rapid pace.”
For more information about Venn Therapeutics, please visit:
About Venn Therapeutics:
Venn Therapeutics is an immuno-oncology company focused on developing novel, best-in-class drugs such as a TGF-β mAb and β-catenin inhibitors, which transform tumor-resident innate immune cells to an anti-tumor phenotype reversing the immunosuppressive microenvironment found within tumors. Venn believes this approach will expand the number of patients who can be effectively treated with immuno-oncology modalities such as PD-1/PD-L1 checkpoint inhibitors.